Ocean Biomedical congratulates Virion on Phase 1b data for VRON-0200

Ocean Biomedical congratulates its JV partner Virion Therapeutics, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker oral presentation highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure, at the 33rd Annual Meeting of APASL, taking place in Kyoto, Japan from March 27 – 31. The late breaker Phase 1 data presented, Virion APASL 2024 Clinical Late Breaker , which includes Virion’s first checkpoint modifier, glycoprotein D, demonstrated that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, following a single intramuscular of 10 chronically HBV-infected patients, representing 641 patient safety days. “These first ever data for a checkpoint modifier containing T cell vaccine of any kind, represent a critical first step towards our goal of bringing a safe, well tolerated, and easy to administer interferon-sparing immunotherapy to HBV-infected patients worldwide,” said Virion’s CEO, Dr. Andrew Luber. Luber added, “VRON-0200 is our lead clinical program and these clinical safety data will further support our proprietary platform technologies and other pipeline programs in development, including VRON-0300, which is for patients with advanced solid tumors.”